Abstract:Background: Non-alcoholic fatty liver disease (NAFLD) is characterized by excessive lipid accumulation and imbalances in lipid metabolism in the liver. Although nuclear receptors (NRs) play a crucial role in hepatic lipid metabolism, the underlying mechanisms of NR regulation in NAFLD remain largely unclear. Methods: Using network analysis and RNA-seq to determine the correlation between NRs and microRNA in human NAFLD patients, we revealed that MIR20B specifically targets PPARA. MIR20B mimic and anti-MIR20B were administered to human HepG2 and Huh-7 cells and mouse primary hepatocytes as well as high-fat diet (HFD)- or methionine-deficient diet (MCD)-fed mice to verify the specific function of MIR20B in NAFLD. We tested the inhibition of the therapeutic effect of a PPARα agonist, fenofibrate, by Mir20b and the synergic effect of combination of fenofibrate with anti-Mir20b in NAFLD mouse model. Results: We revealed that MIR20B specifically targets PPARA through miRNA regulatory network analysis of nuclear receptor genes in NAFLD. The expression of MIR20B was upregulated in free fatty acid (FA)-treated hepatocytes and the livers of both obesity-induced mice and NAFLD patients. Overexpression of MIR20B significantly increased hepatic lipid accumulation and triglyceride levels. Furthermore, MIR20B significantly reduced FA oxidation and mitochondrial biogenesis by targeting PPARA. In Mir20b-introduced mice, the effect of fenofibrate to ameliorate hepatic steatosis was significantly suppressed. Finally, inhibition of Mir20b significantly increased FA oxidation and uptake, resulting in improved insulin sensitivity and a decrease in NAFLD progression. Moreover, combination of fenofibrate and anti-Mir20b exhibited the synergic effect on improvement of NAFLD in MCD-fed mice. Conclusions: Taken together, our results demonstrate that the novel MIR20B targets PPARA, plays a significant role in hepatic lipid metabolism, and present an opportunity for the development of novel therapeutics for NAFLD. Funding: This research was funded by Korea Mouse Phenotyping Project (2016M3A9D5A01952411), the National Research Foundation of Korea (NRF) grant funded by the Korea government (2020R1F1A1061267, 2018R1A5A1024340, NRF-2021R1I1A2041463, 2020R1I1A1A01074940, 2016M3C9A394589324), and the Future-leading Project Research Fund (1.210034.01) of UNIST.

Inhibition of Mir-499-5p Expression Improves Nonalcoholic Fatty Liver Disease

Mir-149 Controls Non-Alcoholic Fatty Liver by Targeting Fgf-21

Aberrant Hepatic Microrna Expression in Nonalcoholic Fatty Liver Disease

Effect of Mirna-10b in Regulating Cellular Steatosis Level by Targeting Ppar-Alpha Expression, A Novel Mechanism for the Pathogenesis of Nafld

Effect Of Mir-34a In Regulating Steatosis By Targeting Ppar Alpha Expression In Nonalcoholic Fatty Liver Disease

MiR-103-3p Promotes Hepatic Steatosis to Aggravate Nonalcoholic Fatty Liver Disease by Targeting of ACOX1

MicroRNA-376b-3p ameliorates nonalcoholic fatty liver disease by targeting FGFR1 and regulating lipid oxidation in hepatocytes

Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease

MiR-192-5p Ameliorates Hepatic Lipid Metabolism in Non-Alcoholic Fatty Liver Disease by Targeting Yy1.

MicroRNA-451 and Genistein Ameliorate Nonalcoholic Steatohepatitis in Mice.

MicroRNA-137-3p Improves Nonalcoholic Fatty Liver Disease Through Activating AMPKα

MicroRNA-20a-5p Ameliorates Non-alcoholic Fatty Liver Disease via Inhibiting the Expression of CD36

Effect of Mir-146 Targeted Hdmcp Up Regulation in the Pathogenesis of Nonalcoholic Steatohepatitis

Mutation of Mir-21 Targets Endogenous Lipoprotein Receptor-Related Protein 6 and Nonalcoholic Fatty Liver Disease.

LncRNA Gm12664–001 Ameliorates Nonalcoholic Fatty Liver Through Modulating Mir-295-5p and CAV1 Expression

Hepatic MIR20B promotes nonalcoholic fatty liver disease by suppressing PPARA

Targeting Hepatic Mir-221/222 for Therapeutic Intervention of Nonalcoholic Steatohepatitis in Mice

Inhibiting miR-27a and miR-142-5p attenuate nonalcoholic fatty liver disease by regulating Nrf2 signaling pathway

LncRNA-H19 Promotes Hepatic Lipogenesis by Directly Regulating Mir-130A/pparγ Axis in Non-Alcoholic Fatty Liver Disease.

MicroRNA-574–5p targeting HOXC6 expression inhibits the hepatocyte lipid uptake to alleviate non-alcoholic fatty liver disease

Role and Mechanisms of Action of Microrna‑21 As Regards the Regulation of the WNT/β‑catenin Signaling Pathway in the Pathogenesis of Non‑alcoholic Fatty Liver Disease.